Is Bilcare a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Bilcare Ltd is a below average quality company .

Is Bilcare undervalued or overvalued?

The key valuation ratios of Bilcare Ltd's currently when compared to its past seem to suggest it is in the Fair zone .

What is Bilcare share price return in the past 10 years?

Bilcare Ltd share price has appreciated 0.7% annually (CAGR) over the past ten years.

Is Bilcare a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Bilcare Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

Bilcare Ltd - Stock Valuation and Financial Performance

Name: Bilcare
Brand: Bilcare

BSE: 526853 | NSE: | Plastic Products | Small Cap

Place order

Bilcare Share Price

₹60.20 -1.48 -2.40%
as on 19-Apr'24 16:01

10 Year X-Ray of Bilcare:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	TTM
ROCE % ⓘ	-2%	-4.7%	-2.8%	-5.4%	-15.2%	-22.3%	-7.7%	3.9%	0.3%	5.7%	-
Value Creation Index ⓘ	-1.1	-1.3	-1.2	-1.4	-2.1	-2.6	-1.6	-0.7	-1.0	-0.6	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	401	331	315	286	258	240	212	304	430	14	18
Sales YoY Gr.	-	-17.5%	-4.8%	-9.5%	-9.8%	-6.9%	-11.7%	43.6%	41.3%	-96.8%	-
Adj EPS ⓘ	-62.5	-78.2	-29.7	-49	-106.7	-133.3	-50	-9.8	-19.5	13.9	170.7
YoY Gr.	-	NA	NA	NA	NA	NA	NA	NA	NA	NA	-
BVPS (₹) ⓘ	363	283.3	264.4	236.3	202.4	68.6	25.1	25.8	18.4	174.3	177.6
Adj Net Profit ⓘ	-147	-184	-69.8	-115	-251	-314	-118	-23.1	-45.8	32.6	402
Cash Flow from Ops. ⓘ	177	-16.7	28.4	37.3	7.2	62.1	71.1	-0.4	46.3	397	-
Debt/CF from Ops. ⓘ	6.9	-69	34.3	24.1	119.4	14	10	-1642.7	14.9	0	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-31.1%	-44.2%	-59.6%	-96.8%
Adj EPS ⓘ	NA	NA	NA	NA
BVPSⓘ	-7.8%	-3%	90.7%	845.3%
Share Price	0.7%	17.9%	5.2%	25.1%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	TTM
Return on Equity % ⓘ	-16.1	-24.2	-10.8	-19.6	-48.6	-98.4	-106.7	-38.6	-88	14.4	97
Op. Profit Mgn % ⓘ	16	6.4	8.6	-1	0.4	0.8	-2.6	8.3	8.6	-37.2	-50.6
Net Profit Mgn % ⓘ	-36.6	-55.6	-22.1	-40.4	-97.5	-130.9	-55.6	-7.6	-10.7	233.2	2241.8
Debt to Equity ⓘ	1.4	1.7	1.6	1.6	1.8	5.4	12	11.2	15.9	0	-
Working Cap Days ⓘ	477	592	448	278	290	300	346	273	229	5,448	247
Cash Conv. Cycle ⓘ	161	212	140	61	64	53	36	40	52	1,079	-99

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 97.00%

Sales growth has been subdued in last 3 years -59.58%

Net Profit has been subdued in last 3 years 0.00%

Sales growth is not so good in last 4 quarters at 8.47%

Latest Financials - Bilcare Ltd.

	Standalone	Consolidated
TTM EPS (₹)	170.7	10.1
TTM Sales (₹ Cr.)	17.9	781
BVPS (₹.) ⓘ	177.6	75.3
Reserves (₹ Cr.) ⓘ	395	154
P/BV ⓘ	0.35	0.82
PE ⓘ	0.36	6.08

From the Market
52 Week Low / High (₹)	42.47 / 95.40
All Time Low / High (₹)	5.00 / 1830.00
Market Cap (₹ Cr.)	145
Equity (₹ Cr.)	23.6
Face Value (₹)	10
Industry PE ⓘ	36

Management X-Ray of Bilcare:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

1.39

0.00

1.39

* Pledged shares as % of Promoter's holding (%)

Valuation of Bilcare

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Bilcare

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Sales	401	331	315	286	258	240	212	304	430	14
Operating Expenses ⓘ	354	310	300	288	258	240	219	279	393	21
Manufacturing Costs	15	15	13	21	21	22	21	30	36	1
Material Costs	272	241	222	212	183	169	143	190	288	5
Employee Cost	19	24	27	29	29	29	27	32	34	6
Other Costs ⓘ	47	31	39	27	25	20	28	27	35	9
Operating Profit ⓘ	48	21	15	-3	0	0	-8	25	37	-7
Operating Profit Margin (%)	11.9%	6.3%	4.8%	-1.0%	-0.1%	0.0%	-3.6%	8.3%	8.5%	-51.1%
Other Income ⓘ	10	4	11	5	14	7	14	14	16	4
Interest ⓘ	147	132	32	48	56	72	69	75	68	0
Depreciation ⓘ	68	106	101	79	304	248	88	35	35	5
Exceptional Items ⓘ	0	0	-117	68	246	0	24	52	27	511
Profit Before Tax ⓘ	-157	-212	-223	-56	-101	-314	-127	-18	-24	503
Tax ⓘ	1	-28	-145	10	-21	1	-24	-19	-6	112
Profit After Tax	-159	-184	-78	-66	-80	-315	-102	2	-18	391
PAT Margin (%)	-39.5%	-55.5%	-24.8%	-23.1%	-31.0%	-131.0%	-48.3%	0.6%	-4.1%	2,794.6%
Adjusted EPS (₹)	-67.4	-78.1	-33.2	-28.0	-34.0	-133.0	-43.5	0.8	-7.6	166.0
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Equity and Liabilities
Shareholders Fund	855	667	623	556	477	161	59	61	43	410
Share Capital ⓘ	24	24	24	24	24	24	24	24	24	24
Reserves ⓘ	831	643	599	533	453	138	36	37	20	387
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	1,228	1,151	976	898	857	868	709	678	690	8
Long Term Debt	1,009	949	773	714	702	714	559	530	537	8
Short Term Debt	219	202	203	184	155	153	150	149	153	0
Trade Payables	31	26	47	50	57	72	51	61	79	6
Others Liabilities ⓘ	524	778	342	426	165	213	69	24	3	30
Total Liabilities ⓘ	2,638	2,623	1,988	1,931	1,555	1,314	887	823	816	454
Fixed Assets
Gross Block	1,522	1,596	1,568	1,587	1,587	1,585	1,586	901	909	55
Accumulated Depreciation	267	379	392	440	743	991	1,079	429	463	39
Net Fixed Assetsⓘ	1,255	1,217	1,177	1,147	844	594	506	473	446	16
CWIP ⓘ	182	125	0	0	0	0	0	0	0	0
Investmentsⓘ	683	682	553	553	514	513	173	89	81	294
Inventories	114	142	52	30	25	32	22	44	56	1
Trade Receivables	105	73	60	49	41	37	39	72	93	9
Cash Equivalents	26	17	11	6	3	7	5	8	5	12
Others Assetsⓘ	274	368	135	146	128	131	141	136	136	122
Total Assets ⓘ	2,638	2,623	1,988	1,931	1,555	1,314	887	823	816	454

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Cash Flow From Operating Activity ⓘ	177	-17	28	37	7	62	71	0	46	397
PBT ⓘ	-121	-184	-223	-124	-346	-314	-151	-70	-51	-8
Adjustment ⓘ	168	207	252	128	286	321	352	136	93	390
Changes in Working Capital ⓘ	178	17	-0	35	69	56	-130	-68	5	17
Tax Paid ⓘ	15	-1	0	-1	-1	-1	-1	1	-1	-1
Cash Flow From Investing Activity ⓘ	-31	-14	9	-48	78	2	11	85	6	181
Capex	-82	-17	0	-50	-1	1	0	1	-1	394
Net Investments	49	1	8	0	1	1	11	84	7	-213
Others ⓘ	3	2	1	1	78	0	0	0	0	0
Cash Flow From Financing Activityⓘ	-153	23	-35	6	-87	-60	-83	-82	-55	-571
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	0	0	0	-48	-56	-72	-69	-75	-68	0
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-153	23	-35	54	-31	12	-14	-8	13	-570
Net Cash Flow ⓘ	-7	-9	2	-5	-1	3	-1	2	-4	7

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Ratios
ROE (%)	-17.41	-24.15	-12.13	-11.18	-15.48	-98.82	-92.77	2.98	-34.16	172.22
ROCE (%)	-0.47	-4.11	-11.22	-0.56	-3.23	-20.49	-6.4	7.58	6.06	87.45
Asset Turnover Ratio	0.15	0.13	0.15	0.16	0.15	0.17	0.19	0.36	0.52	0.02
PAT to CFO Conversion(x)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	0	N/A	1.02
Working Capital Days
Receivable Days	94	98	72	64	62	59	66	67	70	1,332
Inventory Days	115	141	105	48	38	44	46	40	43	745
Payable Days	68	44	60	84	107	140	156	107	88	3,116

Bilcare Ltd Stock News

Bilcare Ltd FAQs

What is the share price of Bilcare?

Company share prices are keep on changing according to the market conditions. The closing price of Bilcare on 19-Apr-2024 16:01 is ₹60.20.

What is the market cap of Bilcare?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 19-Apr-2024 16:01 the market cap of Bilcare stood at ₹145.2.

What is the P/E ratio of Bilcare?

The latest P/E ratio of Bilcare as of 19-Apr-2024 16:01 is 0.36.

What is the P/B ratio of Bilcare?

The latest P/B ratio of Bilcare as of 19-Apr-2024 16:01 is 0.35.

What is the 52-week high and low of Bilcare?

The 52-week high of Bilcare is ₹95.40 and the 52-week low is ₹42.47.

What is the TTM revenue of Bilcare?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Bilcare is ₹17.93 ( Cr.) .

About Bilcare Ltd

Bilcare, incorporated in the year 1987, is engaged in manufacturing pharmaceutical packaging. It has an experience of working with 500 pharma manufacturing companies worldwide.Bilcare is a global leader and an innovation-led packaging solutions provider that partners with the pharmaceutical industry to improve patient healthcare outcomes. The company endeavor to deliver effective and affordable solutions that enhance the speed and quality of drug discovery and help build and protect brands by ensuring the delivery of genuine medicines to patients.

Bilcare PPI offers Innovative Pharmaceutical Packaging Solutions comprising of a wide range of specialty Polymer Films and Aluminum Foils mainly used for packaging of solid dosage pharmaceutical products.

Bilcare GCS provides Global Clinical Material Supplies for new drug discovery projects.

Bilcare Technologies provides Anti-counterfeit (ncID - nonclonableID) solutions for product & people ID authentication and security
The company develops design keeping various aspects into consideration such as end-user, optimum material, composite dosages, on-pack communication, cost-effective, regulatory requirements, etc.It also offers pharmaceutical research and clinical services.

It has representative offices located in Argentina, Bangladesh, Chile, Colombia, Czech Republic, Egypt, France, Indonesia, Iran, Israel, Italy, Jordan, South Korea, Malaysia, Mexico, Pakistan, Saudi Arabia, South Africa, Spain, Taiwan, Thailand, Turkey, Venezuela and Vietnam.

It maintains quality standards prescribed by various agency such USFDA, DEA, IQA, SAP, ISO 9001 and 14001.Bilcare has a global customer base and customers comprise many of the largest global pharmaceutical companies viz. Bristol-Myers Squibb, Dr. Reddyâ€™s, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Ranbaxy, Sanofi-Aventis, Teva to name a few. Bilcare has a strong customer base of over 2,500 customers in over 50 countries worldwide.

For packaging purposes the company uses material like blister films range, aluminium foils, cold formed blisters, wrap systems, closures & containers, flexibles and eco-friendly paper composites.

Bilcare Singapore Pte a wholly owned subsidiary acquired 100 percent stakes in Singapore-based Singular ID. The firm specialises in technology to identify fake drugs.

In 2010 Bilcare won Pharmexcil / Govt of India Patent Award-2009-10.